CAPOX and XELOX — The Tablet-Based Alternative to a Pump

Yes — identical drugs, identical schedule. XELOX became the original abbreviation because Xeloda is the brand name under which capecitabine was first marketed. As generic capecitabine became standard, CAPOX — from capecitabine and oxaliplatin — became preferred in published guidelines. NCCN and ESMO now use CAPOX. Either name on your chart means the same treatment.

Capecitabine is a prodrug — inactive when swallowed, it converts to active 5-fluorouracil through several steps inside the body. The final conversion happens preferentially in tumour tissue, because cancer cells tend to carry higher levels of the enzyme that triggers it. The practical effect is similar to continuous 5-FU infusion, but delivered by tablet rather than pump. Your team may use the two names interchangeably in conversation, which is why the distinction matters.

Oxaliplatin requires intravenous access on each infusion day. Whether that means a surgically placed port or a peripheral vein in the arm depends on your vein access and your team's assessment before your first cycle. What CAPOX removes, compared with FOLFOX, is the pump that runs for about 46 hours after the infusion. You leave the unit when oxaliplatin is complete and take capecitabine tablets at home.

Oxaliplatin affects nerve endings in a way that makes them abnormally reactive to cold — touching cold surfaces or drinking cold liquids triggers the tingling. The exact mechanism is still being studied. This acute sensitivity typically eases in the days between cycles. The cumulative numbness that can develop over multiple infusions is a different effect and is monitored separately by your oncologist.

The number depends on why treatment is being given. In the adjuvant setting — after surgery — NCCN and ESMO guidelines describe typical ranges, and your oncologist will tell you what applies to your situation. For advanced disease, the plan is reviewed across cycles based on how you are responding and tolerating treatment. The number may change — cycles are described as a plan, not a fixed promise.

Yes. CAPOX is used in some gastric (stomach) and gastroesophageal junction cancers, and may be appropriate in other settings depending on tumour type and current guidelines. It is most established in colorectal cancer, where both adjuvant and metastatic uses are well described in guidance from NCCN, ESMO and ASCO. Whether it applies to your specific cancer is a decision your oncologist makes based on tumour biology, stage and your individual fitness.